BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Trombetta BA, Carlyle BC, Koenig AM, Shaw LM, Trojanowski JQ, Wolk DA, Locascio JJ, Arnold SE. The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease. PLoS One 2018;13:e0193707. [PMID: 29505610 DOI: 10.1371/journal.pone.0193707] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Brosseron F, Kleemann K, Kolbe CC, Santarelli F, Castro-Gomez S, Tacik P, Latz E, Jessen F, Heneka MT. Interrelations of Alzheimer´s disease candidate biomarkers neurogranin, fatty acid-binding protein 3 and ferritin to neurodegeneration and neuroinflammation. J Neurochem 2021;157:2210-24. [PMID: 32894885 DOI: 10.1111/jnc.15175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Staurenghi E, Cerrato V, Gamba P, Testa G, Giannelli S, Leoni V, Caccia C, Buffo A, Noble W, Perez-Nievas BG, Leonarduzzi G. Oxysterols present in Alzheimer's disease brain induce synaptotoxicity by activating astrocytes: A major role for lipocalin-2. Redox Biol 2021;39:101837. [PMID: 33360775 DOI: 10.1016/j.redox.2020.101837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Vallabh SM, Minikel EV, Williams VJ, Carlyle BC, McManus AJ, Wennick CD, Bolling A, Trombetta BA, Urick D, Nobuhara CK, Gerber J, Duddy H, Lachmann I, Stehmann C, Collins SJ, Blennow K, Zetterberg H, Arnold SE. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. BMC Med 2020;18:140. [PMID: 32552681 DOI: 10.1186/s12916-020-01608-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
4 Cano A, Turowski P, Ettcheto M, Duskey JT, Tosi G, Sánchez-López E, García ML, Camins A, Souto EB, Ruiz A, Marquié M, Boada M. Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. J Nanobiotechnology 2021;19:122. [PMID: 33926475 DOI: 10.1186/s12951-021-00864-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 McKetney J, Panyard DJ, Johnson SC, Carlsson CM, Engelman CD, Coon JJ. Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease. Proteomics Clin Appl 2021;15:e2000072. [PMID: 33682374 DOI: 10.1002/prca.202000072] [Reference Citation Analysis]
6 Jarero-Basulto JJ, Rivera-Cervantes MC, Gasca-Martínez D, García-Sierra F, Gasca-Martínez Y, Beas-Zárate C. Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease. Pharmaceuticals (Basel) 2020;13:E424. [PMID: 33255969 DOI: 10.3390/ph13120424] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
7 Cao T, Zhou X, Zheng X, Cui Y, Tsien JZ, Li C, Wang H. Histone Deacetylase Inhibitor Alleviates the Neurodegenerative Phenotypes and Histone Dysregulation in Presenilins-Deficient Mice. Front Aging Neurosci 2018;10:137. [PMID: 29867447 DOI: 10.3389/fnagi.2018.00137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Carlyle BC, Kitchen RR, Mattingly Z, Celia AM, Trombetta BA, Das S, Hyman BT, Kivisäkk P, Arnold SE. Technical Performance Evaluation of Olink Proximity Extension Assay for Blood-Based Biomarker Discovery in Longitudinal Studies of Alzheimer's Disease. Front Neurol 2022;13:889647. [DOI: 10.3389/fneur.2022.889647] [Reference Citation Analysis]
9 Mattsson-Carlgren N, Palmqvist S, Blennow K, Hansson O. Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nat Commun 2020;11:6252. [PMID: 33288742 DOI: 10.1038/s41467-020-19957-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
10 [DOI: 10.1101/2019.12.13.19014217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Arnold SE. "Senior Moments" or More? Diagnostic Evaluation of Cognitive Complaints in Older Adults and the Role of Cerebrospinal Fluid Biomarkers. J Appl Lab Med 2020;5:219-24. [PMID: 31811078 DOI: 10.1373/jalm.2019.029546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Carlyle BC, Trombetta BA, Arnold SE. Proteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative Dementias. Proteomes 2018;6:32. [PMID: 30200280 DOI: 10.3390/proteomes6030032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 7.5] [Reference Citation Analysis]
13 Huber RJ. Altered protein secretion in Batten disease. Dis Model Mech 2021;14:dmm049152. [PMID: 34870700 DOI: 10.1242/dmm.049152] [Reference Citation Analysis]
14 Schilde LM, Kösters S, Steinbach S, Schork K, Eisenacher M, Galozzi S, Turewicz M, Barkovits K, Mollenhauer B, Marcus K, May C. Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research. PLoS One 2018;13:e0206478. [PMID: 30496192 DOI: 10.1371/journal.pone.0206478] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
15 Alldred MJ, Lee SH, Ginsberg SD. Adiponectin Modulation by Genotype and Maternal Choline Supplementation in a Mouse Model of Down Syndrome and Alzheimer's Disease. J Clin Med 2021;10:2994. [PMID: 34279477 DOI: 10.3390/jcm10132994] [Reference Citation Analysis]
16 Mullane K, Williams M. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics. Biochem Pharmacol 2018;158:376-401. [PMID: 30273552 DOI: 10.1016/j.bcp.2018.09.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
17 Bjurström MF, Bodelsson M, Irwin MR, Orbjörn C, Hansson O, Mattsson-Carlgren N. Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis. Pain Pract 2021. [PMID: 34143556 DOI: 10.1111/papr.13051] [Reference Citation Analysis]